EGRIFTA SV™ is a newly FDA approved treatment* for Hard Belly (excess hard abdominal fat) in adult patients living with HIV and lipodystrophy.
EGRIFTA SV™ is not indicated for weight loss management; the impact and safety on cardiovascular health have not been studied; and it is not known whether taking EGRIFTA SV™ helps improve compliance with anti-retroviral medications.
EGRIFTA SV™ is a daily treatment that you inject subcutaneously (under the skin) around your lower abdomen (belly).
In some people living with HIV, Hard Belly (excess hard abdominal fat) occurs partly due to a reduced amount of growth hormone, which regulates how fat is stored in your body. Hard Belly fat is a different kind of fat; it lies deeper in the abdomen area, it is harder and firmer than the softer, squishy, regular fat that is just under the skin. Hard Belly fat can be difficult to control with just diet and exercise. In people living with HIV, EGRIFTA SV™ stimulates the production of growth hormone that helps to reduce the amount of Hard Belly fat.
People who used EGRIFTA SV™ continually for one year saw significant reductions in Hard Belly (excess hard abdominal fat) over this time period.
Hard Belly (excess hard abdominal fat) returned when EGRIFTA SV™ was stopped after 6 months of therapy.
Important Information Regarding EGRIFTA SV™ (tesamorelin for injection) and COVID-19 Pandemic.
The full Prescribing Information and Important Safety Information about EGRIFTA SV™ are available here.